Q3 EPS Forecast for Unicycive Therapeutics Lifted by Analyst

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Stock analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Unicycive Therapeutics in a research report issued to clients and investors on Tuesday, September 29th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.39) for the quarter, up from their previous forecast of ($0.40). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at $0.04 EPS, FY2027 earnings at ($0.86) EPS, FY2028 earnings at $2.85 EPS, FY2029 earnings at $3.75 EPS and FY2030 earnings at $4.98 EPS.

Several other equities research analysts have also weighed in on UNCY. Zacks Research raised Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. B. Riley Financial restated a “buy” rating and issued a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a report on Wednesday, August 12th. Guggenheim reiterated a “buy” rating and set a $25.00 target price (down from $37.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 13th. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Finally, Benchmark reissued a “speculative buy” rating and issued a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a research note on Thursday, August 20th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Unicycive Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $18.25.

Unicycive Therapeutics Stock Performance

UNCY opened at $4.22 on Thursday. The company has a fifty day moving average of $5.09 and a two-hundred day moving average of $6.26. The stock has a market capitalization of $117.53 million, a price-to-earnings ratio of -2.41 and a beta of 1.83. Unicycive Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.41.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP increased its position in shares of Unicycive Therapeutics by 85.6% during the second quarter. Seven Fleet Capital Management LP now owns 103,400 shares of the company’s stock worth $521,000 after acquiring an additional 47,700 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Unicycive Therapeutics in the second quarter valued at about $248,000. Bank of America Corp DE grew its stake in Unicycive Therapeutics by 19,327.6% during the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after purchasing an additional 29,378 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Unicycive Therapeutics during the 1st quarter valued at approximately $161,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Unicycive Therapeutics during the 1st quarter worth approximately $940,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Trending Headlines about Unicycive Therapeutics

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: Analysts remain constructive: Unicycive has an average “Moderate Buy” rating, while HC Wainwright reiterated a Buy rating and a $13 price target. The firm improved several longer-term EPS forecasts, including estimates for fiscal 2027 through 2030, suggesting expectations for commercialization and eventual profitability remain intact. Unicycive analyst rating HC Wainwright earnings estimates
• Positive Sentiment: Board addition: Unicycive appointed Meredith Manning, M.B.A., to its board. The addition may strengthen the company’s governance and business expertise as it advances its kidney-disease therapies, although the announcement did not include a new clinical or regulatory milestone. Unicycive appoints Meredith Manning
• Neutral Sentiment: Mixed earnings outlook: HC Wainwright raised its full-year 2026 EPS estimate modestly, but still expects a loss of $1.38 per share. It lowered its 2027 first-quarter estimate while raising estimates for later quarters and projects a return to positive EPS in the fourth quarter of 2027. Separately, a report said HC Wainwright cut its price target, creating a mixed near-term signal. HC Wainwright price target report
• Negative Sentiment: Class-action litigation is the main headwind: Multiple law firms are soliciting investors for a lead-plaintiff role by November 2, 2026, in a lawsuit covering purchases from December 29, 2025, through June 29, 2026. The allegations include reliance on a contract manufacturer with prior FDA current good manufacturing practice deficiencies, which allegedly contributed to a second Complete Response Letter and a reported 39.1% one-day stock collapse. The litigation raises potential financial, regulatory and reputational risks and is likely weighing on UNCY. Unicycive shareholder lawsuit allegations Kaplan Fox class action notice

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.